Back

Homozygous or compound heterozygous variants in DSG2 are mainly causative of Japanese arrhythmogenic right ventricular cardiomyopathy.

26 August 2023 (17:05 - 17:15)
Organised by: Logo
Congress Presentation Part of: Ventricular arrhythmias and sudden cardiac death in cardiomyopathies Arrhythmogenic Right Ventricular Cardiomyopathy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Keiko Sonoda

National Cerebral & Cardiovascular Center, Suita (Japan)

5 More presentations in this session

Presentation thumbnail
Ventricular arrhythmia outcomes in hypertrophic cardiomyopathy from a high level myectomy centre
Doctor M. Gupta (Pittsburgh, US)
Abstract Slides Video
Presentation thumbnail
Long-term follow-up in patients with hypertrophic cardiomyopathy after defibrillator implantation: analysis of appropriate and inappropriate therapy
Miss E. Basse Christensen (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
The added value of abnormal regional myocardial function for risk prediction in arrhythmogenic right ventricular cardiomyopathy
Mr F. Kirkels (Utrecht, NL)
Abstract Slides Video
Presentation thumbnail
The benefit of a double ventricular extra stimuli protocol to improve functional substrate mapping during ablation of ventricular tachycardia. - The S3-VT-FREE project
Mrs M. Regany (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Lipomatous metaplasia is the best CT predictor for conducting channel localization in scar-related ventricular tachycardia ablation
Doctor G. Zucchelli (Pisa, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Ventricular arrhythmias and sudden cardiac death in cardiomyopathies
Video

The Event

Event poster

ESC Congress 2023

26 August 2023 17:05 CET
You may be interested in
thumbnail
Congress Presentation
Genetics of arrhythmogenic cardiomyopathies
thumbnail
Congress Session
Improved understanding of the genetic background of cardiomyopathy
thumbnail
Congress Session
Are we ready to use genetic testing for risk stratification of sudden cardiac death?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources